A Phase I Clinical Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected with the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma. The Johns Hopkins Oncology Center, Baltimore, Maryland
- 1 September 1998
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 9 (13), 1951-1971
- https://doi.org/10.1089/hum.1998.9.13-1951
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Use of Murine Models of Cytokine-Secreting Tumor Vaccines to Study Feasibility and Toxicity Issues Critical to Designing Clinical TrialsJournal of Immunotherapy, 1995
- A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.The Journal of Experimental Medicine, 1994
- Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell LinesScience, 1994
- Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.The Journal of Experimental Medicine, 1994
- The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.The Journal of Experimental Medicine, 1993
- Chemical Splanchnicectomy in Patients with Unresectable Pancreatic Cancer A Prospective Randomized TrialAnnals of Surgery, 1993
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991
- Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4Science, 1991
- Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genesInternational Journal of Cancer, 1991
- Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cellsCancer Immunology, Immunotherapy, 1990